Xueyan Chen, MD, PhD

/content/dam/www/faculty-photos/C/xueyan-chen/xueyan-chen.jpg
Dr. Xueyan Chen MD, PhD
Faculty Member

Xueyan Chen, MD, PhD

Associate Professor, Translational Science and Therapeutics Division, Fred Hutch

Associate Professor
Translational Science and Therapeutics Division, Fred Hutch

Member, Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch

Member
Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch

Physician-pathologist Dr. Xueyan Chen is an expert in the diagnosis and classification of blood and lymph cancers using histology, immunohistochemistry, flow cytometry and molecular genetics. Before joining Fred Hutch, she served as UW Medicine’s Director of Developmental Hematopathology, the section that performs clinical trial testing for biopharmaceutical companies and study groups.

Other Appointments & Affiliations

Affiliate Investigator, Clinical Research Division, Fred Hutch

Affiliate Investigator
Clinical Research Division, Fred Hutch

Associate Professor, Department of Laboratory Medicine and Pathology, University of Washington School of Medicine

Associate Professor, Department of Laboratory Medicine and Pathology
University of Washington School of Medicine

Education

University of Washington, 2011-2012, Fellowship, Hematopathology

University of Wisconsin, 2007-2011, Residency, Anatomic and Clinical Pathology

Tufts University, 2003, PhD (Cell, Molecular & Developmental Biology)

Peking Union Medical College, 1998, MS (Cell Biology)

Beijing Medical University, 1995, MD

Research Interests

Correlate the prognostic impact of clinical response and measurable residual disease in acute myeloid leukemia

Characterize the immunophenotype of hematopoietic neoplasms associated with unique cytogenetic and molecular features

Assess prognostic impact of leukemic stem cells on outcomes in MDS/AML

Clinical Expertise

Diagnosis and classification of blood and lymph cancers using histology, immunohistochemistry, flow cytometry and molecular genetics

Measurable residual disease testing by flow cytometry

Molecular testing including NGS myeloid and lymphoid gene panel and pan-Heme FusionPlex panel

Find a Clinical Trial